Robust Optimization of Chaotropic Chromatography Assay for Lamotrigine and its Two Impurities in Tablets
- 12 Downloads
In this study robust optimization was applied for the development of a reliable analytical assay for lamotrigine, its impurity A, and impurity G in tablets by chaotropic chromatography. The influence of the critical method parameters (acetonitrile content, concentration of chaotropic agent, and pH of the water phase) on the set of selected critical method attributes (retention factor of impurity A, separation factor between lamotrigine and impurity G, and retention factor of impurity G) is studied by Box–Behnken design. Monte Carlo simulations were applied to propagate the errors originating from the model coefficients’ calculation to the selected responses and obtain their predictive distribution. Design space was defined (π ≥ 95%) and a working point selected: 23% of acetonitrile in the mobile phase, 77% of water phase containing 140 mM of perchloric acid, and pH of the water phase adjusted to 2.50. Further robustness testing was performed by Plackett–Burman design to evaluate the quantitative performance of the developed method. The obtained models included not only active main effects but also interactions that were identified as active with the aid of an alias matrix approach and examination of resulting alias plots. The method was validated and its reliability for routine pharmaceutical analysis confirmed.
KeywordsChaotropic chromatography Lamotrigine Impurities Analytical quality by design Robustness testing of quantitative method performance
The authors thank to the Ministry of Education, Science and Technological Development of the Republic of Serbia for supporting this investigation through Project 172052.
Compliance with ethical standards
Conflict of interest
Authors declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 1.EDQM Council of Europe (2017) Pharmacopoeia European, 9th edn. EDQM Council of Europe, Strasburg, p. 2873–2874Google Scholar
- 4.The United States Pharmacopeia (2011) 35/National Formulary 30. United States Pharmacopeia Convention, RockvilleGoogle Scholar
- 6.Vemić A, Kalinić M, Čolović J, Erić S, Malenović A (2017) Recent progress in fundamental understanding and practice of chaotropic chromatography: rationalizing the effects of analytes’ structure with pharmaceutical applications. Adv Chromatogr 2017:1–41Google Scholar
- 18.Lu J, Wei Y, Rustum AM (2010) A stability-indicating reversed-phase high performance liquid chromatography method for simultaneous assay of two corticosteroids and estimation of their related compounds in a pharmaceutical injectable formulation. J Chromatogr A 1217:6932–6941CrossRefPubMedGoogle Scholar
- 25.Debrus B, Lebrun P, Rozet E, Schofield T, Mbinze JK, Marini RD, Rudaz S, Boulanger B, Hubert P (2013) A new method for quality by design robust optimization in liquid chromatography. LC GC Eur 26:370–377Google Scholar
- 27.Nistora I, Lebrun P, Ceccato A, Lecomte F, Slama I, Oprean R, Badarau E, Dufour F, Dossou KSS, Fillet M, Liégeois JF, Hubert P, Rozet E (2013) Implementation of a design space approach for enantiomeric separations in polar organic solvent chromatography. J Pharm Biomed Anal 74:273–283CrossRefGoogle Scholar
- 28.Turpin J, Lukulay PH, Verseput R, Krull I, Swartz M (2008) A quality-by-design methodology for rapid LC method development, Part I. LC GC N Am 26:1190–1197Google Scholar
- 29.Turpin J, Lukulay PH, Verseput R, Krull I, Swartz M (2009) A quality-by-design methodology for rapid LC method development, Part II. LC GC N Am 27:48–61Google Scholar
- 30.Turpin J, Lukulay PH, Verseput R, Krull I, Swartz M (2009) A quality-by-design methodology for rapid LC method development, Part III. LC GC N Am 27:328–340Google Scholar
- 32.Grigori K, Loukas YL, Malenović A, Samara V, Kalaskani A, Dimovasili E, Kalovidouri M, Dotsikas Y (2017) Chemometrically assisted development and validation of LC–MS/MS method for the analysis of potential genotoxic impurities in meropenem active pharmaceutical ingredient. J Pharm Biomed Anal 145:307–314CrossRefPubMedGoogle Scholar
- 33.Iliou K, Malenović A, Loukas Y, Dotsikas Y (2018) Analysis of potential genotoxic impurities in rabeprazole activepharmaceutical ingredient via liquid chromatography-tandem mass spectrometry, following quality-by-design principles for method development. J Pharm Biomed Anal 149:410–418CrossRefPubMedGoogle Scholar
- 35.Andri B, Lebrun P, Dispas A, Klinkenberg R, Streel B, Ziemons E, Marini RD, Hubert PH (2017) Optimization and validation of a fast supercritical fluid chromatography method for the quantitative determination of vitamin D3 and its related impurities. J Chromatogr A 1491:171–181CrossRefPubMedGoogle Scholar
- 36.Furlanetto S, Orlandini S, Pasquini S, Del Bubba M, Pinzauti S (2013) Quality by design approach in the development of a solvent-modified micellar electrokinetic chromatography method: finding the design space for the determination of amitriptyline and its impurities. Ana Chim Acta 802:113–124CrossRefGoogle Scholar
- 43.Schoenmakers P (1986) Optimization of chromatographic selectivity: a guide to method development. Elsevier, AmsterdamGoogle Scholar